There are 1105 resources available
142P - Lenvatinib demonstrates enhanced efficacy in IDH1-mutated cholangiocarcinoma with hyper vascular features on abdominal CT
Presenter: Wen-Chi Wu
Session: Poster Display session
Resources:
Abstract
143P - Claudin-18.2 is a poor prognostic indicator for intrahepatic cholangiocarcinoma
Presenter: Yu Hsuan Kuo
Session: Poster Display session
Resources:
Abstract
144P - The role of adjuvant chemo(radio)therapy in the management of Esophageal keratinizing squamous cell carcinoma
Presenter: Mohamed Elkarany
Session: Poster Display session
Resources:
Abstract
145P - Efficacy and safety in the KEYNOTE-966 study of pembrolizumab (pembro) + gemcitabine and cisplatin (gem/cis) for advanced biliary tract cancer (BTC): Impact of hepatitis B virus (HBV) infection
Presenter: Thomas Yau
Session: Poster Display session
Resources:
Abstract
146P - A retrospective study of the efficacy of gemcitabine combined with capecitabine versus capecitabine alone for biliary tract cancer after curative resection
Presenter: Jiaman Ma
Session: Poster Display session
Resources:
Abstract
147P - Baseline characteristics and molecular testing of Australian patients with IDH1 mutated cholangiocarcinoma: initial results from the phase IIIb ProvIDHe study
Presenter: Timothy Price
Session: Poster Display session
Resources:
Abstract
148P - Real-world data of advanced gallbladder cancers in Eastern India: A single institutional analysis of 100 patients
Presenter: Kiran Ygl
Session: Poster Display session
Resources:
Abstract
149P - Positivity rates of FGFR2 fusion gene or rearrangement and genetic profiling in Asian Cholangiocarcinoma
Presenter: Yuta Maruki
Session: Poster Display session
Resources:
Abstract
150P - The Prognostic Nutritional Index is linked to textbook outcomes and the status of lymphocyte infiltration in patients with perihilar cholangiocarcinoma
Presenter: Qin-qin Liu
Session: Poster Display session
Resources:
Abstract
151P - A new prognostic index for patients with advanced biliary tract cancer treated with cisplatin, gemcitabine and durvalumab
Presenter: Mara Persano
Session: Poster Display session
Resources:
Abstract